GSK Acquires BELLUS Health

GlaxoSmithKline Acquires Sierra Oncology for $1.9bn

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has agreed to acquire late-stage biopharmaceutical company Sierra Oncology for $55 per share in cash, representing an approximate equity value of $1.9 billion. The acquisition, expected to close in Q3 2022 subject to customary approvals, brings momelotinib — a late-stage JAK/ACVR1 inhibitor with demonstrated benefit on symptoms, splenic response and anaemia in myelofibrosis — into GSK's haematology portfolio to strengthen its specialty medicines capability and global commercial reach.

GSK Acquires Elsie Biotechnologies for up to $50M

June 6, 2024

Biotechnology

GSK plc has completed the acquisition of Elsie Biotechnologies, a San Diego–based oligonucleotide-focused biotechnology company, for up to $50 million. The deal integrates Elsie's discovery, synthesis and delivery capabilities into GSK's oligonucleotide R&D platform to accelerate development of therapeutics for chronic hepatitis B, steatotic liver disease and other difficult-to-treat diseases.

GSK Acquires Aiolos Bio for Up to $1.4 Billion

January 9, 2024

Biotechnology

GSK will acquire clinical-stage biopharmaceutical company Aiolos Bio for $1 billion upfront and up to $400 million in regulatory milestone payments, gaining access to AIO-001, a long-acting anti-TSLP monoclonal antibody advancing into Phase II for asthma. The deal expands GSK's respiratory biologics pipeline with a potential best-in-class therapy that may offer dosing as infrequently as every six months.

Nexelis Acquires GSK Vaccines Clinical Bioanalytical Laboratory (Marburg)

January 20, 2021

Biotechnology

Nexelis, a portfolio company of Ampersand Capital Partners, has signed an asset purchase agreement to acquire GSK's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany. Approximately 80 scientists and analysts will transfer to Nexelis, which also entered a five-year strategic collaboration with GSK to continue supporting vaccine development while expanding Nexelis' assay development and high-throughput clinical testing capabilities in Europe.

PCI Pharma Services Acquires Bellwyck Pharma Services

February 11, 2020

Healthcare Services

PCI Pharma Services announced the acquisition of Bellwyck Pharma Services, a Toronto-headquartered clinical and commercial packaging, labeling and clinical trial services provider. The deal adds four GMP-compliant facilities in the U.S., Germany and Canada to PCI's global network and expands PCI's clinical trial service footprint into Canada and continental Europe.

GSK Acquires Affinivax, Inc.

August 16, 2022

Biotechnology

GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.